Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China
Objective The CAPSTONE-1 trial demonstrated that adebrelimab-based immunotherapy yielded a favourable survival benefit compared with chemotherapy for patients with extensive-stage small cell lung cancer (ES-SCLC). This study aims to evaluate the cost-effectiveness of this immunotherapy in the treatm...
Main Authors: | Hao Wang, Yuan Xu, Yujie Zhou, Yunchun Long, Xianhai Xie, Junlin Li |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2024-04-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/14/4/e077090.full |
Similar Items
-
Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
by: Maojin You, et al.
Published: (2022-10-01) -
Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing
by: Yena Gan, et al.
Published: (2023-07-01) -
Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China
by: Hao Wang, et al.
Published: (2023-08-01) -
The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data
by: Bi-Cheng Wang, et al.
Published: (2023-05-01) -
Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study
by: Guanglei Chen, et al.
Published: (2023-12-01)